The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.
Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; et al. (Profiled Authors: Wallin, Anders; Blennow, Kaj)
New York University School of Medicine, NY, USA.
Neurobiology of aging 2009;30(5):682-90.
OBJECTIVES: To longitudinally evaluate five cerebrospinal fluid (CSF) biomarkers in the transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD). METHODS: A baseline and 2-year follow-up clinical and CSF study of 86 subjects, including 22 MCI patients that declined to AD (MCI-AD), 43 MCI that did not deteriorate (MCI-MCI) and 21 controls (NL-NL). All subjects were studied for total and phosphorylated tau (T-tau, P-tau(231)), amyloid beta (Abeta) Abeta(42)/Abeta(40) ratio, isoprostane (IP) as well as P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios. RESULTS: At baseline and at follow-up MCI-AD showed higher levels P-tau(231), T-tau, IP, P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios and lower Abeta(42)/Abeta(40) than MCI-MCI or NL-NL. Baseline P-tau(231) best predicted MCI-AD (80%, p<0.001) followed in accuracy by P-tau(231)/Abeta(42/40) and T-tau/Abeta(42/40) ratios (both 75%, p's<0.001), T-tau (74%, p<0.001), Abeta(42)/Abeta(40) (69%, p<0.01), and IP (68%, p<0.01). Only IP showed longitudinal effects (p<0.05). CONCLUSIONS: P-tau(231) is the strongest predictor of the decline from MCI to AD. IP levels uniquely show longitudinal progression effects. These results suggest the use of CSF biomarkers in secondary prevention trials.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
GANDY, SAMUEL E
15 September 2010 - 30 June 2014
NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE
Total Funding: $ 241,601
GOATE, ALISON M
1 September 2010 - 31 August 2015
NATIONAL INSTITUTE ON AGING
Total Funding: $ 972,692
SMALL, GARY WILLIAM
1 March 2009 - 28 February 2014
NATIONAL INSTITUTE ON AGING
Total Funding: $ 2,905,758
Ozioma C Okonkwo; Michelle M Mielke; H Randall Griffith; Abhay R Moghekar; Richard J O'Brien; Leslie M Shaw; John Q Trojanowski; Marilyn S Albert;Archives of neurology 2011;68(1):113-9.
M Riemenschneider; N Lautenschlager; S Wagenpfeil; J Diehl; A Drzezga; A KurzArchives of neurology 2002;59(11):1729-34.
M J de Leon; S DeSanti; R Zinkowski; P D Mehta; D Pratico; S Segal; H Rusinek; J Li; W Tsui; L A Saint Louis; et al.Neurobiology of aging 2006;27(3):394-401.
Appears in this Publication
Author of this Publication